Pentabind
3 known investors
PentaBind designs programmable aptamers—small RNA/DNA molecules with sub-nanomolar binding affinity—for continuous sensing and diagnostics applications (e.g., monitoring hormones and biomarkers) and targeted therapeutics in oncology and drug delivery. The platform reduces aptamer design cycles from months to ~22 days and delivers application-ready assets rather than just binders.
BiotechDeep TechMedical Devices
Investors · 3
Companies House · registry record
View on Companies House ↗- Registered name
- PENTABIND LTD
- Company number
- 13759900
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 23 Nov 2021
- Registered office
- Scale Space Building, 58 Wood Lane, London, W12 7RZ
- Nature of business (SIC)
- 74909 — Other professional, scientific and technical activities n.e.c.
- Accounts
- last made up to 30 Nov 2025 · next due 31 Aug 2027
- Confirmation statement
- last made up to 29 Oct 2025 · next due 12 Nov 2026
Current officers · 3
- Philip John Haynes — director, appointed 23 Nov 2021
- Hussein Kanji — director, appointed 19 Jun 2025
- Rory Ryan — director, appointed 23 Nov 2021
Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.